A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer

BACKGROUND: We assessed the treatment effect of panitumumab plus best supportive care (BSC) vs BSC on overall survival (OS) in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) and report the first prospective extended RAS analysis in a phase 3 trial. METHODS: P...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae Won, Elme, Anneli, Kusic, Zvonko, Park, Joon Oh, Udrea, Anghel Adrian, Kim, Sun Young, Ahn, Joong Bae, Valencia, Ricardo Villalobos, Krishnan, Srinivasan, Bilic, Ante, Manojlovic, Nebojsa, Dong, Jun, Guan, Xuesong, Lofton-Day, Catherine, Jung, A Scott, Vrdoljak, Eduard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104888/
https://www.ncbi.nlm.nih.gov/pubmed/27736842
http://dx.doi.org/10.1038/bjc.2016.309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104888/
https://www.ncbi.nlm.nih.gov/pubmed/27736842
http://dx.doi.org/10.1038/bjc.2016.309

Ejemplares similares